News | Latest Breaking News Stories & Headlines

Dr Joe Wiley, the chief executive of Amryt Pharma

Italy's Chiesi buys Amryt Pharma for $1.48 billion

Italy's Chiesi Farmaceutici said it will acquire Ireland-based drugmaker Amryt Pharma, which has products and drugs in development for treating rare diseases, in a deal valued at $1.48 billion.

Business • 09 Jan 23

Amryt Pharma gets EU approval for Mycapssa drug

Irish pharmaceutical company Amryt said today that the European Commission had approved its Mycapssa drug in the European Union for the maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide.

Business • 05 Dec 22

Amryt Pharma reports 11th quarter of earnings growth

Amryt Pharma has today reported higher quarterly revenues as it marked its 11th consecutive quarter of positive EBITDA generation.

Business • 03 Nov 22

EMA's positive opinion for Amryt's Mycapssa

Irish pharmaceutical company Amryt said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its Mycapssa drug for the treatment of acromegaly.

Business • 16 Sep 22

Amryt Pharma reports record quarterly revenues

Amryt Pharma has today reported record revenues for the second quarter to the end of June and said that it had started its share buyback programme.

Business • 04 Aug 22

Amryt Pharma secures European approval for EB treatment

Amryt Pharma has secured European Commission approval for its Filsuvez product for the treatment of dystrophic and junctional Epidermolysis Bullosa (EB) in patients six months and older.

Business • 23 Jun 22

Amryt Pharma reports record first quarter revenues

Amryt Pharma has today announced record quarterly revenues as it reaffirmed its full year revenue guidance for 2022.

Business • 04 May 22

Patients with EB must wear bandages on their skin to protect it

EMA recommends authorisation of Amryt's EB treatment

A European Medicines Agency committee has recommended the approval of the use of Amryt Pharma's Filsuvez in the EU for the treatment of partial thickness wounds associated with Epidermolysis Bullosa (EB) in those aged over six months.

Business • 22 Apr 22

Amryt Pharma posts revenue growth of 22% for 2021

Amryt Pharma has announced almost 22% growth in its revenues for 2021 and said it was expecting revenue for 2022 in the range of $260-$270m which represents growth of 17% to 21%.

Business • 09 Mar 22

Joe Wiley said now is the right time to reduce the complexity and significant resources devoted to maintaining a dual listing

Amryt to delist from AIM and trade solely on Nasdaq

Irish pharmaceutical company, Amryt, is to delist its shares from London's Alternative Investment Market (AIM) and trade solely on the Nasdaq Global Select Market.

Business • 22 Nov 21

Amyrt is expecting an FDA decision on its lead development candidate drug on November 30

Amryt records 14.6% rise in third quarter revenues

Revenues at commercial stage biopharma company, Amryt, rose 14.6% in the third quarter of the year, compared to the same period last year.

Business • 03 Nov 21

Dr Joe Wiley, chief executive of Amryt Pharma

Amryt reports higher Q1 revenues and deal with Chiasma

Amryt Pharma has agreed to buy US firm Chiasma in an all stock deal that values the US firm at $330m. The news came as it reported that its first quarter revenues rose by 8.7%.

Business • 05 May 21

Joe Wiley, the CEO of Amryt Pharma, said the company was capable of overcoming the challenges that Covid presented

Amryt Pharma's revenues for 2020 rise by 18.5%

Amryt Pharma has announced record full year results for the year to the end of December as its revenue growth exceeded expectations.

Business • 04 Mar 21

Amryt raises full year revenue guidance

Dublin-headquartered pharmaceutical firm Amryt Pharma has reported an increase in third quarter revenues and also upgraded its full year revenue guidance.

Business • 05 Nov 20

Amryt's Filsuvez succeeds in rare skin disease trial

Amryt Pharma said Filsuvez, its topical therapeutic gel, had demonstrated a significant increase in speed of wound healing in the rare disease Epidermolysis Bullosa (EB) in a late-stage trial.

Business • 09 Sep 20

Amryt seeks Nasdaq listing

Dublin listed Amryt Pharma has filed an application with the US Securities and Exchange Commission (SEC) seeking to have its shares listed for trading on the Nasdaq stock exchange.

Business • 24 Jun 20

Amryt Pharma agrees deal with Aegerion

Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder.

Business • 21 May 19

Joe Wiley, CEO of Amryt Pharma which is focused on finding treatments for rare and orphan diseases, including EB

Amryt Pharma receives FDA approval for EB trials

Amryt Pharma, which is focused on finding treatments for rare and orphan diseases, said the US Food and Drug Administration has granted Investigational New Drug clearance for its AP101 drug.

Business • 10 Sep 18

Revenues for Amryt Pharma's half year came to €6.18m

Amryt Pharma's H1 revenues better than expected

Amryt Pharma has reported better than expected revenues for the six months to the end of June as the company said it had achieved significant milestones in the first half of the year.

Business • 04 Sep 17

Amryt Pharma